by admin | 17 August 2021 | News
Nasally administered Foralumab, once a day for 10 consecutive days, was well-tolerated and produced significant reduction in lung inflammation as assessed by computerized tomography (CT) scanning This anti-inflammatory effect of treatment was strongly supported by a... by admin | 8 July 2021 | News
ADS Ex-Dividend Date Scheduled for July, 09 2021 THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY New York, 8 July 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative... by admin | 2 July 2021 | News
London, New York, 2 July 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today... by admin | 30 June 2021 | News
NEW YORK & LONDON, June 30, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces an interview with the Chairman of its’ Scientific... by admin | 25 June 2021 | News
Tiziana Life Sciences plc (the “Company”) Result of Annual General Meeting At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed. The results of the proxy voting will be available shortly... by admin | 23 June 2021 | News
NEW YORK & LONDON, June 23, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious... by admin | 21 June 2021 | News
NEW YORK & LONDON, June 21, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment of Dr. Kevin... by admin | 17 June 2021 | News
NEW YORK & LONDON, June 17, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases announces that it has submitted a grant to the United... by admin | 2 June 2021 | News
For immediate release 2 June 2021 The Company announces that a letter to Shareholders has been posted advising that the Notice of Annual General Meeting has been made available on the Company’s website:... by admin | 26 May 2021 | News
New York/London, 26 May 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, today provided an update on further analysis of... by admin | 25 May 2021 | News
The first patient with SPMS was dosed on May 24, 2021 with nasally administered Foralumab. The treatment regimen will continue for six months to examine long-term safety, tolerability and clinical responses. Previous clinical studies in healthy volunteers and COVID-19... by admin | 21 May 2021 | News
London, New York, 21 May 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today... by admin | 18 May 2021 | News
London / New York 18 May 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces... by admin | 7 May 2021 | News
NEW YORK & LONDON, May 7, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with CEO and CSO Dr. Kunwar Shailubhai... by admin | 5 May 2021 | News
Objective of this partnership with Takanawa Japan K.K., Pharma Team, is to identify a strategic partner in Japan for further development of Milciclib either alone or in combination with a tyrosine kinase inhibitor (TKI) for treatment of advanced HCC patients in Asian... by admin | 27 April 2021 | News
NEW YORK and LONDON – 27 April 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious... by admin | 13 April 2021 | News
NEW YORK and LONDON , April 13, 2021 – Tiziana Life Sciences plc (NASDAQ:TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited (“Accustem”), intends to file a listing application with the Nasdaq Stock Market shortly... by admin | 30 March 2021 | News
New York/London, 30 March 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the U.S. Food and Drug... by admin | 30 March 2021 | News
NEW YORK and LONDON – 30 March 2021 – Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, is pleased to confirm that, in order to finalise the... by admin | 30 March 2021 | News
Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting Covid-19, this therapeutic approach could be useful for newly identified Covid-19 variants in the UK, South Africa and... by admin | 29 March 2021 | News
NEW YORK and LONDON – 29 March 2021 – Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, clarifies that its Chairman and Founder, Gabriele... by admin | 29 March 2021 | News
NEW YORK and LONDON – 29 March 2021 – Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that the Chairman and Founder, Gabriele... by admin | 26 February 2021 | News
NEW YORK and LONDON – 26 February 2021 — Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with it’s CEO, Dr Kunwar... by admin | 5 February 2021 | News
NEW YORK and LONDON – February 5, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious...